Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men

Edson Duarte Moreira, Anna R. Giuliano, Joel Palefsky, Carlos Aranda Flores, Stephen Goldstone, Daron Ferris, Richard J. Hillman, Harald Moi, Mark H. Stoler, Brooke Marshall, Scott Vuocolo, Dalya Guris, Richard M. Haupt

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background. In this analysis, we examine the incidence and clearance of external genital human papillomavirus (HPV) infection among heterosexual males aged 16-24 years. Methods. A total of 1732 males aged 16-24 years old in the placebo arm of a quadrivalent HPV vaccine trial were included in this analysis. Participants were enrolled from 18 countries in Africa, the Asia-Pacific region, Europe, Latin America, and North America. Subjects underwent anogenital examinations and sampling of the penis, scrotum, and perineal/perianal regions. Results. The incidence rate of any HPV DNA genotype 6, 11, 16, and/or 18 detection was 9.0 cases per 100 person-years. Rates of HPV DNA detection were highest in men from Africa. Median time to clearance of HPV genotypes 6, 11, 16, and 18 DNA was 6.1, 6.1, 7.7, and 6.2 months, respectively. Median time to clearance of persistently detected HPV 6, 11, 16, and 18 DNA was 6.7, 3.2, 9.2, and 4.7 months, respectively. Conclusion. The study results suggest that the acquisition of HPV 6, 11, 16, and/or 18 in males is common and that many of these so-called infections are subsequently cleared, similar to findings for women. Nevertheless, given the high rate of HPV detection among young men, HPV vaccination of males may reduce infection in men and reduce the overall burden of HPV-associated disease in the community.

Original languageEnglish (US)
Pages (from-to)192-199
Number of pages8
JournalJournal of Infectious Diseases
Volume210
Issue number2
DOIs
StatePublished - Jul 15 2014

Fingerprint

Papillomavirus Infections
Heterosexuality
Disease Progression
Human papillomavirus 6
Incidence
Human papillomavirus 11
DNA
Genotype
Papillomavirus Vaccines
Scrotum
Latin America
Penis
North America
Infection
Vaccination
Placebos

Keywords

  • progression

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men. / Moreira, Edson Duarte; Giuliano, Anna R.; Palefsky, Joel; Flores, Carlos Aranda; Goldstone, Stephen; Ferris, Daron; Hillman, Richard J.; Moi, Harald; Stoler, Mark H.; Marshall, Brooke; Vuocolo, Scott; Guris, Dalya; Haupt, Richard M.

In: Journal of Infectious Diseases, Vol. 210, No. 2, 15.07.2014, p. 192-199.

Research output: Contribution to journalArticle

Moreira, ED, Giuliano, AR, Palefsky, J, Flores, CA, Goldstone, S, Ferris, D, Hillman, RJ, Moi, H, Stoler, MH, Marshall, B, Vuocolo, S, Guris, D & Haupt, RM 2014, 'Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men', Journal of Infectious Diseases, vol. 210, no. 2, pp. 192-199. https://doi.org/10.1093/infdis/jiu077
Moreira, Edson Duarte ; Giuliano, Anna R. ; Palefsky, Joel ; Flores, Carlos Aranda ; Goldstone, Stephen ; Ferris, Daron ; Hillman, Richard J. ; Moi, Harald ; Stoler, Mark H. ; Marshall, Brooke ; Vuocolo, Scott ; Guris, Dalya ; Haupt, Richard M. / Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men. In: Journal of Infectious Diseases. 2014 ; Vol. 210, No. 2. pp. 192-199.
@article{02842e57589a46c482c5a60fa69bc8ce,
title = "Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men",
abstract = "Background. In this analysis, we examine the incidence and clearance of external genital human papillomavirus (HPV) infection among heterosexual males aged 16-24 years. Methods. A total of 1732 males aged 16-24 years old in the placebo arm of a quadrivalent HPV vaccine trial were included in this analysis. Participants were enrolled from 18 countries in Africa, the Asia-Pacific region, Europe, Latin America, and North America. Subjects underwent anogenital examinations and sampling of the penis, scrotum, and perineal/perianal regions. Results. The incidence rate of any HPV DNA genotype 6, 11, 16, and/or 18 detection was 9.0 cases per 100 person-years. Rates of HPV DNA detection were highest in men from Africa. Median time to clearance of HPV genotypes 6, 11, 16, and 18 DNA was 6.1, 6.1, 7.7, and 6.2 months, respectively. Median time to clearance of persistently detected HPV 6, 11, 16, and 18 DNA was 6.7, 3.2, 9.2, and 4.7 months, respectively. Conclusion. The study results suggest that the acquisition of HPV 6, 11, 16, and/or 18 in males is common and that many of these so-called infections are subsequently cleared, similar to findings for women. Nevertheless, given the high rate of HPV detection among young men, HPV vaccination of males may reduce infection in men and reduce the overall burden of HPV-associated disease in the community.",
keywords = "progression",
author = "Moreira, {Edson Duarte} and Giuliano, {Anna R.} and Joel Palefsky and Flores, {Carlos Aranda} and Stephen Goldstone and Daron Ferris and Hillman, {Richard J.} and Harald Moi and Stoler, {Mark H.} and Brooke Marshall and Scott Vuocolo and Dalya Guris and Haupt, {Richard M.}",
year = "2014",
month = "7",
day = "15",
doi = "10.1093/infdis/jiu077",
language = "English (US)",
volume = "210",
pages = "192--199",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men

AU - Moreira, Edson Duarte

AU - Giuliano, Anna R.

AU - Palefsky, Joel

AU - Flores, Carlos Aranda

AU - Goldstone, Stephen

AU - Ferris, Daron

AU - Hillman, Richard J.

AU - Moi, Harald

AU - Stoler, Mark H.

AU - Marshall, Brooke

AU - Vuocolo, Scott

AU - Guris, Dalya

AU - Haupt, Richard M.

PY - 2014/7/15

Y1 - 2014/7/15

N2 - Background. In this analysis, we examine the incidence and clearance of external genital human papillomavirus (HPV) infection among heterosexual males aged 16-24 years. Methods. A total of 1732 males aged 16-24 years old in the placebo arm of a quadrivalent HPV vaccine trial were included in this analysis. Participants were enrolled from 18 countries in Africa, the Asia-Pacific region, Europe, Latin America, and North America. Subjects underwent anogenital examinations and sampling of the penis, scrotum, and perineal/perianal regions. Results. The incidence rate of any HPV DNA genotype 6, 11, 16, and/or 18 detection was 9.0 cases per 100 person-years. Rates of HPV DNA detection were highest in men from Africa. Median time to clearance of HPV genotypes 6, 11, 16, and 18 DNA was 6.1, 6.1, 7.7, and 6.2 months, respectively. Median time to clearance of persistently detected HPV 6, 11, 16, and 18 DNA was 6.7, 3.2, 9.2, and 4.7 months, respectively. Conclusion. The study results suggest that the acquisition of HPV 6, 11, 16, and/or 18 in males is common and that many of these so-called infections are subsequently cleared, similar to findings for women. Nevertheless, given the high rate of HPV detection among young men, HPV vaccination of males may reduce infection in men and reduce the overall burden of HPV-associated disease in the community.

AB - Background. In this analysis, we examine the incidence and clearance of external genital human papillomavirus (HPV) infection among heterosexual males aged 16-24 years. Methods. A total of 1732 males aged 16-24 years old in the placebo arm of a quadrivalent HPV vaccine trial were included in this analysis. Participants were enrolled from 18 countries in Africa, the Asia-Pacific region, Europe, Latin America, and North America. Subjects underwent anogenital examinations and sampling of the penis, scrotum, and perineal/perianal regions. Results. The incidence rate of any HPV DNA genotype 6, 11, 16, and/or 18 detection was 9.0 cases per 100 person-years. Rates of HPV DNA detection were highest in men from Africa. Median time to clearance of HPV genotypes 6, 11, 16, and 18 DNA was 6.1, 6.1, 7.7, and 6.2 months, respectively. Median time to clearance of persistently detected HPV 6, 11, 16, and 18 DNA was 6.7, 3.2, 9.2, and 4.7 months, respectively. Conclusion. The study results suggest that the acquisition of HPV 6, 11, 16, and/or 18 in males is common and that many of these so-called infections are subsequently cleared, similar to findings for women. Nevertheless, given the high rate of HPV detection among young men, HPV vaccination of males may reduce infection in men and reduce the overall burden of HPV-associated disease in the community.

KW - progression

UR - http://www.scopus.com/inward/record.url?scp=84904012845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904012845&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiu077

DO - 10.1093/infdis/jiu077

M3 - Article

C2 - 24495910

AN - SCOPUS:84904012845

VL - 210

SP - 192

EP - 199

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -